Previous 10 | Next 10 |
Ionis Pharmaceuticals ( NASDAQ: IONS ) is scheduled to announce Q4 earnings results on Wednesday, February 22nd, before market open. The consensus EPS Estimate is -$0.86 (-161.0% Y/Y) and the consensus Revenue Estimate is $160.21M (-63.6% Y/Y). Over the last 1 year, IONS has...
Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting PR Newswire...
Summary Tweedy, Browne’s 13F portfolio value decreased from $2.27B to $1.88B this quarter. They increased Ionis Pharmaceuticals while reducing most of the other stakes. Berkshire Hathaway at ~20% of the portfolio is the largest position. This article is part of a se...
Ionis to hold fourth quarter and full year 2022 financial results webcast PR Newswire Webcast scheduled for Wednesday, February 22 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. 8, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS...
Summary Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. The company's total revenue was $2,508.5 million in the third quarter of 2022, down 9.7% from the previous year. The decline ...
Ionis announces GSK has advanced bepirovirsen into Phase 3 development PR Newswire Initiation of the Phase 3 program expands Ionis' late-stage pipeline to 7 medicines in 9 indications CARLSBAD, Calif. , Feb. 1, 2023 /PRNewswire/ -- Ionis Pharmaceuti...
RNA therapeutics company Ionis Pharmaceuticals ( NASDAQ: IONS ) announced Tuesday that the FDA granted the Fast Track designation for its investigational therapy olezarsen for familial chylomicronemia syndrome (FCS), a rare form of dyslipidemia. The FDA offers the Fast Track desig...
Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome PR Newswire FCS is a rare and debilitating genetic disease often leading to significant risk of acute, potentially fatal pancreatitis If approved, olez...
Summary Royalty Pharma plc is an interesting investment fund that buys pharmaceutical royalties and generates a non-correlated yield. With the depressed biotech sector valuation and increasing cost of capital with rising interest rates, we expect explosive growth in deal-making for Roya...
Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set o...
Ionis to hold second quarter 2024 financial results webcast PR Newswire Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced ...
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease PR Newswire Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition...